← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT07737704

NCT07737704 Assessment of a New Enhanced Xenograft in Open Maxillary Sinus Augmentation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07737704
Status Recruiting
Phase Phase 2, Phase 3
Sponsor Misr International University
Condition Maxillary Sinus Floor Augmentation
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-08-10
Primary Completion 2027-06-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Xenograftmaxillary sinus membrane elevation and stabilization.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 30 participants in total. It began in 2026-08-10 with a primary completion date of 2027-06-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Implant supported dental restorations are sometimes challenging with decreased bone height in the posterior maxilla. The goal of this study is to test an augmentation bone substitute in elevating the maxillary sinus floor; in terms of soft tissue reaction, formed bone height as well as structure. Bone substitute will be compared to a graftless method of bone augmentation depending on participants' bodies forming bone in the defective area. Participants will: * Undergo lateral maxillary sinus floor elevation with bone substitute or graftless method. * Record postoperative swelling and pain through the follow up period. * Take radiographs for evaluation of the formed bone before placing dental implants.

Eligibility Criteria

Inclusion Criteria: * Adult male/female patients above the age of 18. * Patients with one or more teeth requiring implant supported dental restoration in atrophic posterior maxilla. * Alveolar bone height less than 5 mm at the defective site. * Good oral hygiene. * Patient's consensual agreement to be enrolled in the study. Exclusion Criteria: * Medically compromised patients with conditions contraindicating surgery (eg. uncontrolled diabetics, bisphosphonate intake, radio or chemotherapy). * Patients with active infection at or related to the site of surgery (eg. acute sinusitis). * Heavy smokers. * Patients not indicated for an implant supported restoration at the time of enrollement. (Patients developing any medical condition that interferes with the outcomes after enrolment in the study will be excluded).

Contact & Investigator

Central Contact

Ramy H El Shater, MDS

✉ ramy.hamdy@miuegypt.edu.eg

📞 +201014111431

Frequently Asked Questions

Who can join the NCT07737704 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Maxillary Sinus Floor Augmentation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07737704 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07737704 currently recruiting?

Yes, NCT07737704 is actively recruiting participants. Contact the research team at ramy.hamdy@miuegypt.edu.eg for enrollment information.

Where is the NCT07737704 trial being conducted?

This trial is being conducted at Ismailia, Egypt, Ismailia, Egypt, Ismailia, Egypt.

Who is sponsoring the NCT07737704 clinical trial?

NCT07737704 is sponsored by Misr International University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology